Cohance Lifesciences Announces Q4 and FY26 Results, Sets Growth Expectations for FY27

Cohance Lifesciences Announces Q4 and FY26 Results, Sets Growth Expectations for FY27​

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, today announced its audited financial results for the fiscal year ended March 31, 2026, along with unaudited results for the quarter ended March 31, 2026. The announcement details the company's performance as a global Contract Development and Manufacturing Organization (CDMO), maintaining its focus on high-value platforms and expansion across various life science segments.

Financial Performance Highlights​

The company reported substantial financials for the year ended March 31, 2026, showcasing performance across both standalone and consolidated entities.

In the Financial Year 2026 (FY26):

• Consolidated Revenue from Operations: ₹ 2,302.64 crores (up from ₹ 2,677.71 crores in FY25).
• Consolidated Total Income: ₹ 2,302.64 crores.
• Consolidated Net Profit After Tax (NPAT): ₹ 150.12 crores.
• Consolidated Operating Cash Flow: ₹ 368.32 crores.

The company's cash flow generation remained healthy, with the net cash flow generated from operating activities for the year at ₹ 671.35 crores.

The annual audited financial results for both standalone and consolidated entities are presented below:

Core Business Performance and Operational Strategy​

The management emphasized that the company's CDMO platform is differentiated and technology-led, spanning ADCs, nucleic acid chemistries, small molecules, and complex chemistries.

Q4 and FY26 Operational Snapshot​

During Q4 FY26, the company reported revenue from operations of ₹ 6.19 billion. Adjusted EBITDA margins were at 21% for the quarter, translating to an Adjusted EBITDA of ₹ 1.30 billion.

The company’s revenue stream remains diversified across several business segments:

Strategic Growth Outlook for FY27​

While FY26 was described as a transition year, Cohance management projects that growth is expected to return from the second half of FY27 onwards. The company anticipates Q1 FY27 to be the low point for both revenue and EBITDA due to factors like shipment phasing and seasonal cost increases, leading to a recovery from 2H FY27.

Key Business Drivers​

The company reported that its strengths include:

• Pipeline: The total Phase III pipeline now stands at 10 programmes, with consistent Requests for Proposals (RFP) inflows across small molecules, ADC, and complex chemistries.
• Leadership: The leadership structure was strengthened under Mr. Umang Vohra, focusing on an owner-manager mindset and improved execution discipline.
• Technology: The company continues to enhance its core technology capabilities, particularly in ADC and Oligonucleotides, with the NJ Bio platform and the Sapala platform driving customized payload development and pipeline build-up.

Corporate Details​

Company Name: Cohance Lifesciences Limited
Former Name: Suven Pharmaceuticals Limited
Registered Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra, India, 400093.

COHANCE Stock Price Movement​

Today, Cohance Lifesciences Limited shares edged higher, gaining ₹2.15 to settle at ₹484.65, marking a 0.45% increase for the session. The stock maintained robust interest throughout the day, handling a significant total traded volume of 5.57 million shares.